Soleno Therapeutics Inc
F:6XC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Soleno Therapeutics Inc
F:6XC
|
US |
|
R
|
RCF Acquisition Corp
NYSE:RCFA
|
US |
|
Union Insurance Co Ltd
TWSE:2816
|
TW |
Soleno Therapeutics Inc
Soleno Therapeutics is a biopharmaceutical company focused on medicines for rare diseases, especially disorders that affect appetite and behavior. Its main product is an oral prescription drug for people with Prader-Willi syndrome, a genetic condition that can cause extreme, hard-to-control hunger. The company develops the drug, works through the regulatory and commercial process, and then sells it through the specialty pharmaceutical channel if approved and marketed. The business makes money mainly by selling its prescription medicine to specialty pharmacies, health plans, and other healthcare buyers that cover rare-disease treatments. Because its lead product is used in a niche patient group, Soleno depends on physician diagnosis, insurance reimbursement, and specialty distribution rather than broad retail sales. That makes it a focused drug company tied to one main medical need instead of a large, diversified pharmaceutical portfolio. What makes Soleno's role different is that it targets a rare condition with very limited treatment options, so the company is trying to become the specialist supplier for that specific patient population. In beginner-investor terms, it is a single-product biotech story built around turning a scientific drug candidate into an ongoing commercial medicine for a small, well-defined market.
Soleno Therapeutics is a biopharmaceutical company focused on medicines for rare diseases, especially disorders that affect appetite and behavior. Its main product is an oral prescription drug for people with Prader-Willi syndrome, a genetic condition that can cause extreme, hard-to-control hunger. The company develops the drug, works through the regulatory and commercial process, and then sells it through the specialty pharmaceutical channel if approved and marketed.
The business makes money mainly by selling its prescription medicine to specialty pharmacies, health plans, and other healthcare buyers that cover rare-disease treatments. Because its lead product is used in a niche patient group, Soleno depends on physician diagnosis, insurance reimbursement, and specialty distribution rather than broad retail sales. That makes it a focused drug company tied to one main medical need instead of a large, diversified pharmaceutical portfolio.
What makes Soleno's role different is that it targets a rare condition with very limited treatment options, so the company is trying to become the specialist supplier for that specific patient population. In beginner-investor terms, it is a single-product biotech story built around turning a scientific drug candidate into an ongoing commercial medicine for a small, well-defined market.
Blowout Q4 Revenue: Soleno delivered Q4 revenue of $91.7 million, nearly 40% higher than the previous quarter, and $190.4 million for the full year despite less than nine months of sales.
Profitability Achieved: The company reported positive full-year net income of $20.9 million and cash flow from operations of $48.7 million in Q4.
Strong Launch Momentum: Since VYKAT XR's launch, 1,250 patient start forms were received, representing 12.5% of the addressable U.S. market, with 859 active patients at year-end.
Durable Uptake & Adherence: VYKAT XR discontinuation rates remain low at about 12% due to adverse events and 15% overall, with high adherence and sustained refill rates.
Cash Position Bolstered: Soleno ended the year with $506.1 million in cash and securities, even after a $100 million share repurchase.
First-in-Class Medicine: VYKAT XR is the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome (PWS), with payers covering over 180 million lives.
EU Expansion Progress: European regulatory review is advancing, with a potential EMA decision expected around mid-2026, and commercialization plans underway.
Pipeline Growth: Soleno plans to expand VYKAT XR into new indications, beginning with glycogen storage disease type 1 (GSD1), with clinical development to start later in 2026.
